Deng et al. noted that MiR-488 targeted inhibition of PFKFB3 reduces lactate release and helps to improve the sensitivity of 5-FU and oxaliplatin to CRC cells.17 This evidence concerns the gene PFKFB3 and colorectal carcinoma.